| Literature DB >> 28619957 |
Yurdagül Uzunhan1,2, Hilario Nunes3,2, Florence Jeny3,2, Maxime Lacroix3,4, Sophie Brun5, Pierre-Yves Brillet3,4, Emmanuel Martinod6, Marie-France Carette7, Diane Bouvry3,2, Caroline Charlier8,9, Fanny Lanternier8,9, Carole Planès3,2, Abdellatif Tazi10, Olivier Lortholary8,9, Robert P Baughman11, Dominique Valeyre3,2.
Abstract
Chronic pulmonary aspergillosis (CPA) complicating sarcoidosis (SA) is associated with high mortality, and there is a lack of clarity regarding the relative contributions of SA or CPA.This was a retrospective single-centre study on CPA-SA.In total, 65 patients (44 men), aged 41.4±13.5 and 48.3±11.9 years at the time of SA and CPA diagnoses, respectively, were included between 1980 and 2015. Of these, 64 had fibrocystic SA, most often advanced, with composite physiological index (CPI) >40 (65% of patients) and pulmonary hypertension (PH) (31%), and 41 patients (63%) were treated for SA (corticosteroids or immunosuppressive drugs). Chronic cavitary pulmonary aspergillosis (CCPA) was the most frequent CPA pattern. Regarding treatment, 55 patients required long-term antifungals, 14 interventional radiology, 11 resection surgery and two transplantation. Nearly half of the patients (27; 41.5%) died (mean age 55.8 years); 73% of the patients achieved 5-year survival and 61% 10-year survival. Death most often resulted from advanced SA and rarely from haemoptysis. CPI, fibrosis extent and PH predicted survival. Comparison with paired healthy controls without CPA did not show any difference in survival, but a higher percentage of patients had high-risk mould exposure.CPA occurs in advanced pulmonary SA. CPA-SA is associated with high mortality due to the underlying advanced SA rather than to the CPA. CPI, fibrosis extent and PH best predict outcome.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28619957 DOI: 10.1183/13993003.02396-2016
Source DB: PubMed Journal: Eur Respir J ISSN: 0903-1936 Impact factor: 16.671